CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma

Author(s):

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

Date/Time: Tuesday, June 30, 2020 at 7 PM EST

This OncLive^® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma (NHL). Join our leading experts as they discuss important topics and considerations surrounding CAR T-Cell therapy and patients with High-Risk Non-Hodgkin Lymphoma.

Click here to register today!

Course Topics:

Rationale for CAR T-Cell therapy in patients with lymphoma
Review of CAR T-Cell activity in aggressive lymphoma
Review of CAR T-Cell activity in indolent lymphoma and CLL
Activity of CAR T-Cell in myeloma
Review progress on short term and longer term toxicity of CAR T-Cells
Real-world data compared with results seen on clinical trials
Navigating referrals in the community
Future directions for CAR T-Cell therapy in NHL

Chair
Andre H. Goy, MD
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Hackensack, NJ

Sponsored by: